- Home
- ETW vs NEO Comparison
ETW vs NEO Comparison
Compare ETW & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ETW
Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | ETW | NEO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.8M | 1.0B |
| IPO Year | 2005 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ETW | NEO |
|---|---|---|
| Price | $9.31 | $8.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 323.9K | ★ 1.6M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.01 | $4.72 |
| 52 Week High | $9.60 | $13.74 |
Technical Indicators
Market Signals| Indicator | ETW | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 56.26 |
| Support Level | $9.28 | $8.68 |
| Resistance Level | $9.41 | $8.84 |
| Average True Range (ATR) | 0.10 | 0.48 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 63.13 | 93.98 |
Price Performance
Historical ComparisonAbout ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.